LIF Polyclonal Antibody

Rabbit Anti-LIF Polyclonal Antibody

Product Specifications

Background

Leukemia inhibitory factor encoded by LIF is a pleiotropic cytokine with roles in several different systems. It is involved in the induction of hematopoietic differentiation in normal and myeloid leukemia cells, induction of neuronal cell differentiation, regulator of mesenchymal to epithelial conversion during kidney development, and may also have a role in immune tolerance at the maternal-fetal interface. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene.

CAS Number

9007-83-4

Product Name Alternative

LIF; HILDA; Leukemia inhibitory factor; LIF; Differentiation-stimulating factor; D factor; Melanoma-derived LPL inhibitor; MLPLI; Emfilermin

Gene ID

3976

Accession Number

P15018

Reactivity

Human, Rat, Mouse

Immunogen

Synthesized peptide derived from the C-terminal region of human LIF

Clonality

Polyclonal

Tag

Leukemia inhibitory factor

Applications

WB, IHC, IF, ELISA

Purification Method

The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

Concentration

1 mg/ml

Molecular Weight

25kD

Precautions

The product listed herein is for research use only and is not intended for use in human or clinical diagnosis. Suggested applications of our products are not recommendations to use our products in violation of any patent or as a license. We cannot be responsible for patent infringements or other violations that may occur with the use of this product.

Shipping Conditions

Gel pack with blue ice.

Storage Conditions

Stable for one year at -20°C from date of shipment. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Aliquot to avoid repeated freezing and thawing.

Notes

LIF Polyclonal Antibody detects endogenous levels of LIF protein.

Observed Molecular Weight

Formulation

Liquid solution

Buffer pH

Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

Applications Notes

Optimal working dilutions should be determined experimentally by the investigator. Suggested starting dilutions are as follows: WB 1:500-1:2000; IHC: 1:100-300; ELISA 1:20000; IF 1:50-200